Found: 34
Select item for more details and to access through your institution.
Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-77072-8
- By:
- Publication type:
- Article
Prospective phase II trial of [<sup>68</sup>Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy.
- Published in:
- EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01164-9
- By:
- Publication type:
- Article
A convolutional neural network for total tumor segmentation in [<sup>64</sup>Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.
- Published in:
- EJNMMI Research, 2022, v. 12, p. 1, doi. 10.1186/s13550-022-00901-2
- By:
- Publication type:
- Article
Routine Use of [<sup>64</sup>Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 10, p. 1, doi. 10.2967/jnumed.124.267939
- By:
- Publication type:
- Article
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGAE[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine Neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 252, doi. 10.2967/jnumed.122.264383
- By:
- Publication type:
- Article
Prospective phase II trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT imaging of integrin α<sub>v</sub>β<sub>3</sub> for prognostication in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264383
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT imaging of integrin αvβ3 for prognostication in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Prospective phase II trial of prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263177
- By:
- Publication type:
- Article
Semi‐automatic tumor delineation for evaluation of <sup>64</sup>Cu‐DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi‐automatic tumor delineation for evaluation of <sup>64</sup>Cu‐ DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi‐automatic tumor delineation for evaluation of <sup>64</sup>Cu‐ DOTATATE PET/CT in patientswith neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi-automatic tumor delineation for evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi-automatic tumor delineation for evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi-automatic tumor delineation for evaluation of <sup>64</sup>Cu- DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi-automatic tumor delineation for evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
Semi-automatic tumor delineation for evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.258392
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression2 free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression - free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression2 free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.240143
- By:
- Publication type:
- Article
<sup>64</sup>Cu-DOTATATE PET/CT and prediction of overall and progression free survival in patients with neuroendocrine neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 3, p. 1, doi. 10.2967/jnumed.119.24014
- By:
- Publication type:
- Article
Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.
- Published in:
- Diagnostics (2075-4418), 2023, v. 13, n. 21, p. 3303, doi. 10.3390/diagnostics13213303
- By:
- Publication type:
- Article
First-in-Human Study of [ 68 Ga]Ga-NODAGA-E[c(RGDyK)] 2 PET for Integrin α v β 3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 4, p. 851, doi. 10.3390/diagnostics12040851
- By:
- Publication type:
- Article